Navigation Links
The Treatment Landscape for Thyroid Carcinoma Will Change Dramatically Through 2021
Date:2/4/2013

BURLINGTON, Mass., Feb. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2021, the treatment landscape for thyroid carcinoma will change dramatically in the United States and Europe due to the expected approval of several new therapies. In addition to Exelixis's Cometriq (cabozantinib) for advanced medullary thyroid carcinomas (MTC)—which was approved in the U.S. late last year—the other emerging agents in the thyroid carcinoma space are Bayer HealthCare/Onyx Pharmaceuticals' Nexavar (sorafenib), Eisai's lenvatinib, Genentech/Roche's Zelboraf (vemurafenib), GlaxoSmithKline's combination of dabrafenib and trametinib and OXiGENE's Zybrestat (fosbretabulin). A large focus of drug development has been on the radioiodine (RAI)-refractory, differentiated thyroid carcinoma (DTC) patient population.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

"These therapies will likely be high priced but will dramatically increase treatment options for RAI-refractory thyroid carcinoma patient populations for which there is no standard of care," said Decision Resources Analyst Gemma McConnell , Ph.D. 

According to Niche Markets and Rare Diseases: Thyroid Carcinoma, the overall incidence of thyroid carcinoma will increase over the next decade, driven by demographic change and more sensitive diagnostic procedures. In particular, the incidence of papillary thyroid carcinoma (PTC), which accounts for the vast majority of all diagnosed cases of thyroid carcinoma, will rise. In 2021, the number of incident cases of PTC will increase by approximately 23 percent, thereby contributing to an increase in the size of the drug-treatable population.

The report also finds that the opportunity for uptake of emerging agents developed for DTC will be constrained by small patient populations in the locally advanced or advanced disease setting. The majority of DTC cases are usually diagnosed early and have a good prognosis with current treatment of surgery, typically a total thyroidectomy, and RAI ablation therapy.

"Surgery and RAI therapy is the primary treatment approach for patients whose disease is considered resectable and the tumor is RAI-avid," Dr. McConnell said. "As long as a patient remains RAI-avid, RAI will remain the treatment of choice, constraining the opportunity for emerging therapies."

About Thyroid Carcinoma
Thyroid Carcinoma is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
2. B. Braun Smart Infusion Pump Technology Advances Patient Safety and Treatment Efficiency
3. FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol for Maintenance Treatment of COPD
4. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
5. Researchers at Scripps to Study Possible New Treatment for Parkinsons Disease
6. Foundation Venture Capital Group Invests In Start-Up Working to Reduce Side Effects of Parkinsons Treatment
7. US Vitamin Injections Discusses Bursitis Treatment with B12 Shots
8. Varian Equipment Selected to Equip New Cancer Center in Algeria and Enable More Advanced Radiotherapy Treatments for Patients
9. The Shift from Treatment to Prevention: A Drive towards Cutting Healthcare Costs
10. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
11. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
Breaking Medicine News(10 mins):